Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GZMB | P10144 | 20/20 | 0.62 |
| ▸ | CASP3 | P42574 | 2/20 | 0.50 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24390643 | 0.90 | GZMB (0.65) | GZMB | |
| SCHEMBL24390650 | 0.90 | GZMB (0.66) | GZMBCASP3CASP8 | |
| SCHEMBL24390641 | 0.89 | GZMB (0.66) | GZMB | |
| SCHEMBL26417148 | 0.88 | GZMB (0.57) | GZMBCASP3CASP8 | |
| SCHEMBL24390644 | 0.88 | GZMB (0.60) | GZMBCASP3CASP8 | |
| SCHEMBL26010781 | 0.87 | GZMB (0.69) | GZMB | |
| SCHEMBL24390645 | 0.87 | GZMB (0.60) | GZMB | |
| SCHEMBL30429989 | 0.87 | GZMB (0.71) | GZMB | |
| SCHEMBL15485596 | 0.86 | GZMB (0.83) | GZMB | |
| SCHEMBL22697207 | 0.86 | GZMB (0.83) | GZMB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230132386-A9 | GRANZYME B DIRECTED IMAGING AND THERAPY | CYTOSITE BIOPHARMA INC. | 2023-04-27 | — | — | US | disclosed |
| US-20230132386-A9 | GRANZYME B DIRECTED IMAGING AND THERAPY | CYTOSITE BIOPHARMA INC. | 2023-04-27 | — | — | US | disclosed |
| US-20230132386-A9 | GRANZYME B DIRECTED IMAGING AND THERAPY | CYTOSITE BIOPHARMA INC. | 2023-04-27 | — | — | US | disclosed |
| US-20220135593-A1 | GRANZYME B DIRECTED IMAGING AND THERAPY | CYTOSITE BIOPHARMA INC (US) | 2022-05-05 | — | — | US | disclosed |
| US-20220135593-A1 | GRANZYME B DIRECTED IMAGING AND THERAPY | CYTOSITE BIOPHARMA INC (US) | 2022-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230132386-A9 | GRANZYME B DIRECTED IMAGING AND THERAPY | GZMB, PRF1, CTSB | GZMB 1/4885CASP3 478/4885CASP8 901/4885 |
| US-20220135593-A1 | GRANZYME B DIRECTED IMAGING AND THERAPY | GZMB, PRF1, CTSB | GZMB 1/4885CASP3 478/4885CASP8 901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.